Mitchell Mathis, MD
- 4Articles
- 23.2KReads
- 2011–2020Active
- 35Collaborators
- 236Citations
About
Mitchell Mathis, MD, has published extensively on clinical and regulatory aspects of psychiatric disorders, including major depressive disorder, schizophrenia, and schizoaffective disorders. His work has addressed topics such as placebo response trends in schizophrenia trials, maintenance treatment strategies for depression, and pharmacogenetic guidance for drug dosing. Mathis has contributed to articles examining the US Food and Drug Administration's perspectives on antidepressant approvals and dosing recommendations. His research spans from 2011 to 2020 and includes collaborations with other experts in the field.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
